Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05545891 | NOT YET RECRUITING | Trichotillomania (Hair-Pulling Disorder)

Aripiprazole in Body Focused Repetitive Behaviors
Sponsor:

University of Chicago

Brief Summary:

This study is 6 weeks long and involves subjects taking aripiprazole or placebo. If they are randomly assigned to the aripiprazole arm and are eligible to participate in the study, they will begin by taking 5mg once daily of aripiprazole for two weeks, then 10mg once daily for the remaining three weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either aripiprazole or placebo on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.

Condition or disease

Trichotillomania (Hair-Pulling Disorder)

Dermatillomania

Intervention/treatment

Placebo

Aripiprazole

Phase

PHASE2

Detailed Description:

The goal of the proposed study is to evaluate the efficacy and safety of aripiprazole in 100 subjects with DSM-5 trichotillomania (TTM) or skin picking disorder (SPD). The hypothesis to be tested is that aripiprazole will be effective and well tolerated in patients with BFRBs (trichotillomania or skin picking disorder) compared to placebo. The proposed study will provide needed data on the treatment of disabling disorders that currently lack a clearly effective treatment. This will be one of few studies assessing the use of pharmacotherapy for the treatment of TTM and SPD in adults. Assessing the efficacy and safety of aripiprazole will help inform clinicians about additional treatment options for adults suffering from this disorder.

Study Type : INTERVENTIONAL
Estimated Enrollment : 100 participants
Masking : QUADRUPLE
Primary Purpose : TREATMENT
Official Title : A Double-Blind, Placebo Controlled Study of Aripiprazole in Body Focused Repetitive Behaviors
Actual Study Start Date : 2025-11
Estimated Primary Completion Date : 2026-10
Estimated Study Completion Date : 2026-10

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Men and women age ≥18 years
  • 2. current DSM-5 trichotillomania or skin picking disorder; and
  • 3. Ability to understand and sign the consent form.
Exclusion Criteria
  • 1. Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
  • 2. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
  • 3. Subjects considered an immediate suicide risk based on the Columbia Suicide Severity rating Scale (C-SSRS) (www.cssrs.columbia.edu/docs)
  • 4. Past 12-month DSM-5 diagnosis of psychosis, bipolar disorder, mania, or a substance or alcohol use disorder
  • 5. Illegal substance use based on urine toxicology screening
  • 6. Stable dose of medications for at least the past 3 months
  • 7. Previous treatment with aripiprazole
  • 8. Cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent
Aripiprazole in Body Focused Repetitive Behaviors

Location Details

NCT05545891

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

United States, Illinois

University of Chicago

Chicago, Illinois, United States, 60637